VijayPD Ceutical FY26 net profit rises to ₹505.75 lakh

VijayPD Ceutical Limited reported a net profit of ₹505.75 lakh for the financial year ended March 31, 2026, marking a 7.4% increase compared to ₹471.03 lakh in the previous year. The company's revenue from operations for FY26 stood at ₹9,895.64 lakh, slightly lower than the ₹10,023.40 lakh recorded in FY25. The board of directors approved the audited financial results at its meeting held on May 30, 2026.

The statutory auditor, J. D. Shah Associates, issued an unmodified opinion on the standalone financial results. The auditor emphasized that the company incurred aggregate expenditure of ₹418.24 lakhs related to its Initial Public Offering (IPO), which was adjusted against the Securities Premium Account. The company raised ₹1,925.00 lakhs through the IPO, listing on the SME Platform of NSE Limited on October 7, 2025.

Financial Performance

For the year ended March 31, 2026, VijayPD Ceutical's total income was ₹10,298.74 lakh. Total expenses for the period amounted to ₹9,645.19 lakh. The company reported a profit before tax of ₹652.30 lakh, with a tax expense of ₹146.55 lakh. Earnings per share (EPS) for the year stood at ₹3.03 on a basic and diluted basis, down from ₹3.77 in the previous year.

Metric	FY26 (₹ in Lakhs)	FY25 (₹ in Lakhs)
Revenue from Operations	9,895.64	10,023.40
Total Income	10,298.74	10,098.72
Total Expenses	9,645.19	9,458.91
Net Profit	505.75	471.03
EPS (Basic)	3.03	3.77

IPO Proceeds Utilization

The company utilized ₹1,069.25 lakh of the total IPO proceeds by March 31, 2026. The funds were deployed towards capital expenditure, repayment of borrowings, general corporate purposes, and issue-related expenses. A certificate from the auditors confirmed that the utilization of funds was in agreement with the books of accounts and that there was no deviation from the stated objects.

Particulars	Amount (₹ in Lakhs)
Total IPO Proceeds	1,925.00
Utilized till March 31, 2026	1,069.25
Pending to be Utilized	855.75

Consolidated Results and Acquisition

The company also filed its audited consolidated financial results for the half year and year ended March 31, 2026. The consolidated results include the financials of subsidiary M/s Zen Pharmaceuticals, which was acquired on December 1, 2025. On a consolidated basis, the profit for the year ended March 31, 2026, was ₹500.10 lakh. The auditor noted that since the company did not have a subsidiary in the previous year, comparative consolidated figures are not applicable.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	-6.54%	-14.64%	+90.90%	+124.93%	+124.93%

VijayPD Ceutical Limited reported a net profit of ₹505.75 lakh for the financial year ended March 31, 2026, reflecting a 7.4% increase compared to ₹471.03 lakh in the previous year. Revenue from operations for FY26 stood at ₹9,895.64 lakh, slightly lower than the ₹10,023.40 lakh recorded in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 30, 2026.

The statutory auditors, M/s. J. D. Shah Associates, issued an audit report with an unmodified opinion on the financial results. However, the auditors drew attention to an aggregate expenditure of ₹418.24 lakhs incurred in connection with the company's Initial Public Offering (IPO). This amount, which includes certain costs in excess of the issue-related expenses disclosed in the Draft Prospectus, was adjusted against the Securities Premium Account in accordance with the Companies Act, 2013.

Financial Performance

For the year ended March 31, 2026, the company reported a total income of ₹10,298.74 lakh, up from ₹10,098.72 lakh in the prior year. Total expenses increased to ₹9,645.19 lakh from ₹9,458.91 lakh in FY25. The company’s earnings per share (EPS) for the year stood at ₹3.03 on a basic and diluted basis, compared to ₹3.77 in the previous year.

Particulars	Year ended March 31, 2026 (₹ in Lakhs)	Year ended March 31, 2025 (₹ in Lakhs)
Revenue from Operations	9,895.64	10,023.40
Total Income	10,298.74	10,098.72
Total Expenses	9,645.19	9,458.91
Profit for the Period	505.75	471.03
Earnings Per Share (Basic)	3.03	3.77

IPO Proceeds and Utilization

The company successfully completed its IPO, raising proceeds of ₹1,925.00 lakh. As of March 31, 2026, the company had utilized ₹1,069.25 lakh of the total proceeds. The utilization included ₹227.08 lakh for funding capital expenditure, ₹510.00 lakh for the repayment of borrowings, ₹74.17 lakh for general corporate purposes, and ₹258.00 lakh for issue-related expenses. The remaining ₹855.75 lakh is pending utilization and is held in fixed deposits and current accounts.

Corporate Developments

During the year, the company entered into a Share Purchase Agreement to acquire a 100% stake in M/s Siddarth Drugs Private Limited on April 7, 2026. Additionally, the Board re-appointed M/s. Sodha & Associates, Chartered Accountants, as the Internal Auditor for the financial year 2026-27. The consolidated financial results for FY26 include the financials of subsidiary M/s Zen Pharmaceutical from December 1, 2025.